Post by CLIRNET

74,871 followers

The U.S. FDA has approved ๐ƒ๐ž๐ฑ๐ญ๐ซ๐จ๐ฆ๐ž๐ญ๐ก๐จ๐ซ๐ฉ๐ก๐š๐ง ๐ก๐ฒ๐๐ซ๐จ๐›๐ซ๐จ๐ฆ๐ข๐๐žโ€“๐๐ฎ๐ฉ๐ซ๐จ๐ฉ๐ข๐จ๐ง ๐ก๐ฒ๐๐ซ๐จ๐œ๐ก๐ฅ๐จ๐ซ๐ข๐๐ž ๐Ÿ๐จ๐ซ ๐š๐ ๐ข๐ญ๐š๐ญ๐ข๐จ๐ง ๐ข๐ง ๐€๐ฅ๐ณ๐ก๐ž๐ข๐ฆ๐ž๐ซโ€™๐ฌ ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž ๐๐ž๐ฆ๐ž๐ง๐ญ๐ข๐šโ€”the first ๐ง๐จ๐ง-๐š๐ง๐ญ๐ข๐ฉ๐ฌ๐ฒ๐œ๐ก๐จ๐ญ๐ข๐œ option. โฃ โฃ Two randomized trials showed significant CMAI improvement and longer time to relapse vs placebo. โฃ โฃ For India, this highlights an emerging non-antipsychotic approach to a high-burden symptom area, pending local regulatory evaluation.โฃ โฃ #AlzheimersDisease #DementiaCare #Neuropsychiatryโฃ #GeriatricMedicine #FDAApproval #ClinicalTrials #Neurologyโฃ

Post content